Author: Geneos Therapeutics, Inc.

Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy

November 2, 2026
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

October 21, 2026

Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy